What role does ECP play in patients with CTCL with progressive disease and/or those who have not responded to initial systemic, immune-modifying, or skin-directed therapy?

What role does ECP play in patients with CTCL with progressive disease and/or those who have not responded to initial systemic, immune-modifying, or skin-directed therapy?

What role does ECP play in patients with CTCL with progressive disease and/or those who have not responded to initial systemic, immune-modifying, or skin-directed therapy?


Created by

CMEducation Resources IQ&A Extracorporeal Photopheresis Intelligence Zone | The Multi-Specialty Perspective

Presenter

Julia Scarisbrick, MD

Julia Scarisbrick, MD

Dr. Julia Scarisbrick Consultant Dermatologist & Cutaneous Lymphoma Lead at the University Hospital Birmingham, UK